Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Immunohistochemistry (IHC) for the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) biomarkers has prognostic and therapeutic value in breast cancer. This study aimed to compare the expression of ER, PR, and HER2 between paired malignant effusions and tissue samples of breast cancer.
Methods: Our electronic archive was searched for all effusions diagnosed as breast carcinomas within a pre-defined period (January 2018-October 2021). Next, their cell blocks (CBs) were subjected to ER, PR, HER2 IHC, or in situ hybridization, in addition to EGFR IHC. The expression of hormone receptors (HRs) and HER2 was subsequently compared between tissue and effusion cytology samples derived from the same patients.
Results: Only 2/76 (2.6%) of the breast cancer patients analyzed showed a malignant effusion at their initial presentation. ER, PR, and HER2 discordance rates between paired malignant effusions and tissue samples obtained at initial diagnosis were 24.3% (17/73), 40.8% (29/71), and 9.1% (6/66), respectively. The HR-/HER2- status was found more often at effusions compared to paired tissue biopsies obtained at initial diagnosis (30/70 vs. 17/70; p < 0.001). In addition, the HR-/HER2- status was significantly associated with an earlier development of a malignant effusion, when found at initial diagnosis (p < 0.001; log-rank test), first recurrence/metastasis (either solid or effusion) (p = 0.012; log-rank test), effusion samples (p = 0.007; log-rank test), and any tumor sample obtained (p = 0.009; log-rank test). Lastly, EGFR overexpression in the HR-/HER2- effusion samples was significantly associated with a shorter post-effusion survival (p = 0.019; log-rank test).
Conclusion: Serous effusion cytology provides high-quality material for ancillary techniques, especially when CBs are prepared, reflecting cancer heterogeneity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000533912 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of a novel mechanical valve versus stented bioprosthetic valves for isolated mitral valve replacement in patients older than 65 years.
JTCVS Open
August 2025
Division of Cardiac Surgery, IRCCS Azienda Ospedaliera-Universitaria di Bologna, Bologna, Italy.
Objective: To compare early and long-term clinical outcomes of bioprosthetic versus mechanical (On-X) mitral valve replacement (MVR) in patients aged 65 years and older.
Methods: This single-center retrospective study included consecutive patients equal to or older than 65 years underwent isolated MVR from 2005 to 2023. A propensity score-matched analysis was performed to compare early- and long-term clinical outcomes between patients with bioprostheses and mechanical On-X valve.
Association Between Revascularization and 30-Day Survival of Ischemic Cardiomyopathy Patients in Dr. Hasan Sadikin General Hospital.
Vasc Health Risk Manag
September 2025
Department of Cardiology and Vascular Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
Introduction: Ischemic cardiomyopathy is the leading cause of heart failure and associated with increased morbidity and mortality. The role of percutaneous coronary intervention (PCI) in term of increasing survival and cardiovascular outcomes in ischemic cardiomyopathy remains unclear.
Purpose: To evaluate whether revascularization is associated with 30-day survival in ischemic cardiomyopathy in Dr.
Biologic Therapy and Malignancy Risk in Psoriasis: A Retrospective Cohort Study.
J Dermatol
September 2025
Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
The long-term impact of biologic therapy on malignancy risk in patients with psoriasis remains unclear. Given the chronic nature of psoriasis and the increasing use of biologics, understanding their long-term safety profile is crucial. This study aimed to compare the incidence of malignancy between patients receiving continuous biologic therapy and those treated with topical monotherapy.
View Article and Find Full Text PDFPerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.
Nat Med
September 2025
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Immune checkpoint blockade (ICB) is standard of care in advanced diffuse pleural mesothelioma (DPM), but its role in the perioperative management of DPM is unclear. In tandem, circulating tumor DNA (ctDNA) ultra-sensitive residual disease detection has shown promise in providing a molecular readout of ICB efficacy across resectable cancers. This phase 2 trial investigated neoadjuvant nivolumab and nivolumab/ipilimumab in resectable DPM along with tumor-informed liquid biopsy residual disease assessments.
View Article and Find Full Text PDFBackground: Acute kidney injury (AKI) in patients with liver cirrhosis represents a significant clinical challenge with high mortality rates. This study aimed to develop and validate a machine learning-based prediction model for 28-day mortality in AKI patients with liver cirrhosis using the MIMIC-IV database.
Methods: This retrospective study analyzed data from 4,168 AKI patients, including 601 with concurrent liver cirrhosis, from the MIMIC-IV database.